All Articles

Mechanistic roles and clinical applications of tertiary lymphoid structures in colorectal cancer drug resistance

An epithelial-mesenchymal transition-related gene signature predicts prognosis, immune infiltration, and drug sensitivity in colorectal cancer

Novel N-chloroacetyl-2-pyrazoline analogs with 2-naphthyl and ferrocenyl groups: targeting histamine receptor H1 to overcome colorectal cancer drug resistance

RCC1 knockdown sensitizes drug-resistant colorectal cancer to 5-fluorouracil or doxorubicin by impairing DNA repair

KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer

CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis

Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer

Mitochondria in colorectal cancer stem cells - a target in drug resistance

Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

RIP140 regulates POLK gene expression and the response to alkylating drugs in colon cancer cells

Emerging actionable targets to treat therapy-resistant colorectal cancers

Auranofin and its analogs as prospective agents for the treatment of colorectal cancer

Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review

Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro

Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines